Pain · Research Phase
Neuropeptide FF
No lawful US pathway
01 · Overview
Neuropeptide FF (NPFF) is a member of the RFamide peptide family, characterized by an arginine-phenylalanine-amide motif at the C-terminus. It acts on the G protein-coupled receptors NPFF1 and NPFF2, and RFamide peptides and their receptors modulate nociception and the analgesic effects of opiates in rodents (PMID 25324831).
NPFF is widely distributed in the central nervous system and has been described as having both pronociceptive and anti-opioid roles. That profile has generated interest in targeting NPFF receptors as adjuncts to opioid analgesia.
02 · Research summary & key findings
In rats and mice, the orally active NPFF receptor antagonist RF313 improved the analgesic efficacy of opiates and prevented the development of long-lasting opioid-induced hyperalgesia, without major side effects in mice (PMID 28288815). Broader rodent work supports a modulatory role for RFamide peptides and their receptors in basal and chronic pain and in opiate analgesia (PMID 25324831). All of this evidence is preclinical; no human clinical trials targeting NPFF receptors have been reported, and therapeutic development remains at the discovery stage.
03 · Regulatory status
Neuropeptide FF is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
No lawful pathway today
Neuropeptide FF is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 2 FDA-approved compounds in Pain
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for injury recovery and tissue repair?
Neuropeptide FF is a research compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on injury recovery and tissue repair, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Intracerebroventricular
- Subcutaneous injection
References
- [1]Involvement of Mammalian RF-Amide Peptides and Their Receptors in the Modulation of Nociception in Rodents Front Endocrinol (Lausanne), 2014. PMID 25324831
- [2]RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents Neuropharmacology, 2017. PMID 28288815
Primary literature
- PubMed: "Neuropeptide FF"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Neuropeptide FF"
Registered interventional and observational studies, including status and phase.
- PubChem: "Neuropeptide FF"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Pain
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.